Communiqués Kancera AB

Actions

KAN

SE0015658570

Temps Différé Nasdaq Stockholm Autres places de cotation 14:23:32 05/07/2024			Varia. 5j.	Varia. 1 janv.
1,69 ^SEK	+4,06 %		+7,64 %	-62,82 %

17/05	Kancera AB (publ) annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
16/05	Kancera AB (publ) fournit une mise à jour opérationnelle concernant l'étude Kandova et signale une augmentation du recrutement de patients	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Kancera - Underestimated optionality	22/05	AQ
Interim Report First Quarter 2024, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851	17/05	AQ
Kancera provides operational update regarding the KANDOVA study and reports increased patient recruitment	16/05	AQ
Kancera appoints new Chief Scientific Officer and extends management team	08/05	AQ
Kancera meets the primary objectives of the KAND145 clinical phase I study	03/05	AQ
Kancera announces the outcome of the company's rights issue	20/03	AQ
Kancera publishes prospectus in connection with the company’s rights issue	01/03	AQ
Kancera resolves on a rights issue of approximately SEK 121.9 million	23/02	AQ
Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851	23/02	AQ
Kancera signs license agreement and obtains global commercial rights to the results from the FRACTAL study	23/02	AQ
Kancera presents the statistical analysis of top line data from the FRACTAL study	06/02	AQ
Kancera reports positive top line results from the FRACTAL study	20/12	AQ
Kancera provides operational update in connection with release of financial interim report for third quarter 2023	17/11	AQ
Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851	17/11	AQ
Kancera reports that the phase I study of KAND145 has received regulatory approval	23/10/23	AQ
Kancera announces that the FRACTAL top line results are expected to be presented by the end of December 2023	13/10/23	AQ
Kancera appoints new Chief Medical Officer	01/09/23	AQ
Kancera provides operational update in connection with release of financial interim report for second quarter	18/08/23	AQ
Interim Report Second Quarter April 1 – June 30 2023 Kancera AB (publ.), org.no. 556806-8851	18/08/23	AQ
Newly published research publication confirms the potential for Kancera’s fractalkine blocker KAND567 in cardiovascular disease	24/07/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Kancera AB

Actions

KAN

SE0015658570

Communiqués

Filtres